Liquidia Corporation (NASDAQ:LQDA – Get Free Report) insider Jason Adair sold 7,863 shares of the business’s stock in a transaction on Monday, July 13th. The stock was sold at an average price of $71.51, for a total transaction of $562,283.13. Following the transaction, the insider directly owned 217,126 shares in the company, valued at approximately $15,526,680.26. The trade was a 3.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Jason Adair also recently made the following trade(s):
- On Monday, April 27th, Jason Adair sold 688 shares of Liquidia stock. The shares were sold at an average price of $41.65, for a total transaction of $28,655.20.
Liquidia Stock Up 7.4%
LQDA traded up $5.28 during trading hours on Tuesday, reaching $76.49. 1,153,916 shares of the stock traded hands, compared to its average volume of 2,219,263. Liquidia Corporation has a fifty-two week low of $14.04 and a fifty-two week high of $82.96. The company has a market cap of $6.80 billion, a price-to-earnings ratio of 546.40 and a beta of 0.55. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. The firm’s fifty day simple moving average is $66.37 and its two-hundred day simple moving average is $47.52.
Analyst Ratings Changes
A number of research analysts recently commented on LQDA shares. Zacks Research raised Liquidia from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 5th. Wells Fargo & Company upped their target price on Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a research report on Tuesday, May 12th. HC Wainwright increased their target price on Liquidia from $67.00 to $75.00 and gave the company a “buy” rating in a research note on Friday, June 5th. Bank of America reissued a “neutral” rating and set a $79.00 price target (up from $64.00) on shares of Liquidia in a research report on Monday, June 29th. Finally, Wall Street Zen cut shares of Liquidia from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 27th. Three investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Liquidia presently has an average rating of “Moderate Buy” and a consensus target price of $68.88.
Check Out Our Latest Stock Report on LQDA
Institutional Trading of Liquidia
Institutional investors and hedge funds have recently made changes to their positions in the stock. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Liquidia in the 4th quarter worth approximately $25,000. Covestor Ltd grew its stake in Liquidia by 41.9% during the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after buying an additional 359 shares during the last quarter. FNY Investment Advisers LLC bought a new position in Liquidia during the 3rd quarter worth $34,000. NewEdge Advisors LLC acquired a new stake in Liquidia in the second quarter worth $25,000. Finally, Fluent Financial LLC acquired a new stake in Liquidia in the second quarter worth $287,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.
About Liquidia
Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.
The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).
Read More
- Five stocks we like better than Liquidia
- Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet
- 3 Overlooked Energy ETFs Delivering Strong Returns and Income
- 3 Space Stocks That Could Outshine SpaceX After Its IPO
- JPMorgan’s Q2 Strength Gives the Stock Rally New Support
Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.
